Alçın Göksel, Şanlı Yasemin, Yeğen Gülçin, Kaytan Sağlam Esra, Çermik Tevfik Fikret
University of Health and Sciences, İstanbul Training and Research Hospital, Clinic of Nuclear Medicine, İstanbul, Turkey.
İstanbul University, İstanbul Faculty of Medicine, Department of Nuclear Medicine, İstanbul, Turkey.
Mol Imaging Radionucl Ther. 2020 Apr 29;29(2):65-71. doi: 10.4274/mirt.galenos.2020.40316.
The aim of this study was to evaluate the impact of maximum standard uptake value (SUV) of the primary tumor and locoregional metastatic lymph node in predicting survival in patients with the preoperative rectal adenocarcinoma.
One hundred and fifteen patients [mean age ± standard deviation (SD): 58.7±11.4 years] with biopsy-proven rectal adenocarcinoma underwent F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) imaging for the staging were included in this study. All patients were followed-up for a minimum of 12 months (mean ± SD: 29.7±13.5 months). Tumor-node-metastasis 2017 clinical staging, SUV of the primary rectal tumor and locoregional lymph nodes on the PET/CT studies were evaluated.
All patients had increased FDG activity of the primary tumor. The mean ± SD SUV of the primary tumor and locoregional metastatic lymph node were 21.0±9.1 and 4.6±2.8, respectively. Primary tumor SUV did not have an effect on predicting survival (p=0.525) however locoregional metastatic lymph node SUV had an effect (p<0.05) on predicting survival. Clinical stage of the disease was a factor predicting survival (p<0.001).
F-FDG PET/CT is an effective imaging modality for detecting primary tumors and metastases in rectal adenocarcinoma and clinical stage assessment with PET/CT had an effect on predicting survival. Furthermore, in our study locoregional lymph node SUV was defined as a factor in predicting survival.
本研究旨在评估原发性肿瘤和局部区域转移淋巴结的最大标准摄取值（SUV）对术前直肠腺癌患者生存预测的影响。
本研究纳入了115例经活检证实为直肠腺癌的患者[平均年龄±标准差（SD）：58.7±11.4岁]，这些患者接受了F-氟脱氧葡萄糖（FDG）正电子发射断层扫描/计算机断层扫描（PET/CT）成像以进行分期。所有患者均进行了至少12个月的随访（平均±标准差：29.7±13.5个月）。评估了2017年肿瘤-淋巴结-转移临床分期、PET/CT研究中直肠原发性肿瘤和局部区域淋巴结的SUV。
所有患者原发性肿瘤的FDG活性均升高。原发性肿瘤和局部区域转移淋巴结的平均±标准差SUV分别为21.0±9.1和4.6±2.8。原发性肿瘤SUV对生存预测没有影响（p=0.525），然而局部区域转移淋巴结SUV对生存预测有影响（p<0.05）。疾病的临床分期是生存预测的一个因素（p<0.001）。
F-FDG PET/CT是检测直肠腺癌原发性肿瘤和转移灶的有效成像方式，PET/CT进行临床分期评估对生存预测有影响。此外，在我们的研究中，局部区域淋巴结SUV被确定为生存预测的一个因素。
